Iheezo, approved in September 2022, is an ocular surface anesthesia used during cataract surgeries.
The Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through reimbursement status for Harrow’s Iheezo (chloroprocaine hydrochloride ophthalmic gel), which is indicated for ocular surface anesthesia. Beginning April 1, 2023, and for the three years thereafter, Iheezo will be eligible for separate reimbursement outside of the surgical bundled payment in both the ambulatory surgery center (ASC) and hospital outpatient department (HOPD) settings of care.
CMS previously approved the issuance of a permanent, product-specific J‑Code (J2403), enabling access to Iheezo for ophthalmologists, optometrists, and retina specialists for the in‑office setting of care.
Iheezo will be reimbursed using the average sales price (pricing is the average sales price after considering any discounts) +6% but the ASP price won’t be established until the beginning of next year. Until then, it will be reimbursed at wholesale acquisition cost ($544) +3%.
CMS grants pass-through status to certain new and innovative medical devices, drugs, and biological products. Drugs that are administered in the hospital-based outpatient department and ambulatory surgical center settings can have pass-through status. CMS collects utilization data during this pass-through period, and the agency uses this information when determining how to adjust the payment rate for the service using the product after transitional pass-through status expires.
For pass-through products used in a hospital setting, CMS reimburses 100% of the cost for Medicare Part B patients, and no copayment applies. When a pass-through drug or device is used in an ambulatory surgical center, however, the 20% copayment does apply.
Iheezo is a single-patient use, physician‑administered, ophthalmic gel preparation for ocular surface anesthesia. It was approved by the FDA on Sept. 26, 2022. The safety and efficacy were demonstrated in three human clinical studies, including an active-controlled, observer‑masked study that evaluated the administration of Iheezo in patients undergoing cataract surgery. This study demonstrated that Iheezo worked rapidly (about 1 to 1.5 minutes) and provided sufficient anesthesia to successfully perform the surgical procedure (on average lasting 22 minutes). Additionally, no patient required a supplemental treatment to complete the surgical procedure.
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More
Don’t Overlook the Importance of Annual Dilated Retinal Exams
July 15th 2024The annual dilated retinal exam, a unique tool which uses drops to dilate the pupil, is not just about eye health. It offers a comprehensive view of a member's overall well-being, potentially identifying serious health issues at an early stage.
Read More